Abdera Therapeutics
Lana Janes, Ph.D., serves as Chief Operating Officer at Abdera Therapeutics and has held various leadership roles as Co-Founder and Senior Vice President of Operations and Innovation, Co-Founder, President, and Interim Chief Executive Officer. Lana is also a member of the Board of Directors at the Centre for Probe Development and Commercialization and LifeSciences BC. Additionally, Lana contributes to the Creative Destruction Lab as an Associate in the Health Stream and serves as a Venture Partner and Entrepreneur In Residence at adMare BioInnovations. Academic credentials include a Bachelor's Degree in Chemistry from Harvard University and further education at McGill University.
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.